{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:59:09Z","timestamp":1784156349443,"version":"3.55.0"},"reference-count":35,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,6,17]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess if 12 novel circulating biomarkers, when added to \u2018standard predictors\u2019 available in general practice, could improve the 10-year prediction of cardiovascular events and mortality in patients with stable coronary heart disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>The patients participated as placebo receiving patients in the randomised clarithromycin for patients with stable coronary artery disease (CLARICOR) trial at a random time in their disease trajectory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Five Copenhagen University cardiology departments and a coordinating centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>1998 participants with stable coronary artery disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Death and composite of myocardial infarction, unstable angina pectoris, cerebrovascular disease and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When only \u2018standard predictors\u2019 were included, 83.4% of all-cause death predictions and 68.4% of composite outcome predictions were correct. Log(calprotectin) and log(cathepsin-S) were not associated (p\u22650.01) with the outcomes, not even as single predictors. Adding the remaining 10 biomarkers (high-sensitive assay cardiac troponin T; neutrophil gelatinase-associated lipocalin; osteoprotegerin; N-terminal pro-B-type natriuretic peptide; tumour necrosis factor receptor 1 and 2; pregnancy-associated plasma protein A; endostatin; YKL40; cathepsin-B), which were all individually significantly associated with the prediction of the two outcomes, increased the figures to 84.7% and 69.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>When \u2018standard predictors\u2019 routinely available in general practices are used for risk assessment in consecutively sampled patients with stable coronary artery disease, the addition of 10 novel biomarkers to the prediction model improved the correct prediction of all-cause death and the composite outcome by &lt;1.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00121550\">NCT00121550<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-033720","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T06:20:46Z","timestamp":1597990846000},"page":"e033720","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00121550","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Per","family":"Winkel","sequence":"first","affiliation":[{"name":"The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2120","authenticated-orcid":false,"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, The Faculty of Heath Sciences, University of Southern Denmark, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Hilden","sequence":"additional","affiliation":[{"name":"Section of Biostatistics, Department of Public Health Research, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorm Boje","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Kj\u00f8ller","sequence":"additional","affiliation":[{"name":"Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Sajadieh","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kastrup","sequence":"additional","affiliation":[{"name":"Rigshopitalet, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J\u00f8rn","family":"Kolmos","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Odense University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper Karmark","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Bjerre","sequence":"additional","affiliation":[{"name":"The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"\u00c4rnl\u00f6v","sequence":"additional","affiliation":[{"name":"Family Medicine and Primary Care, Karolinska Universitetssjukhuset, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-0799","authenticated-orcid":false,"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"2025121223445558000_10.8.e033720.1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000808"},{"key":"2025121223445558000_10.8.e033720.2","doi-asserted-by":"crossref","DOI":"10.1186\/s41512-017-0009-y","article-title":"Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial","volume":"1","author":"Winkel","year":"2017","journal-title":"Diagn Progn Res"},{"key":"2025121223445558000_10.8.e033720.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38666.653600.55"},{"key":"2025121223445558000_10.8.e033720.4","first-page":"14","article-title":"Intervention with clarithromycin in patients with stable coronary heart disease","volume":"1","author":"Hansen","year":"2001","journal-title":"Heartdrug"},{"key":"2025121223445558000_10.8.e033720.5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008299"},{"key":"2025121223445558000_10.8.e033720.6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2018.09.006","article-title":"Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study","volume":"278","author":"Wuopio","year":"2018","journal-title":"Atherosclerosis"},{"key":"2025121223445558000_10.8.e033720.7","doi-asserted-by":"publisher","DOI":"10.3109\/00365513.2010.538081"},{"key":"2025121223445558000_10.8.e033720.8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014634","article-title":"Prognosis and reclassification by YKL-40 in stable coronary artery disease","volume":"9","author":"Schroder","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025121223445558000_10.8.e033720.9","doi-asserted-by":"publisher","DOI":"10.1177\/2047487313492099"},{"key":"2025121223445558000_10.8.e033720.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.10.025"},{"key":"2025121223445558000_10.8.e033720.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125992","article-title":"Calprotectin and platelet aggregation in patients with stable coronary artery disease","volume":"10","author":"Larsen","year":"2015","journal-title":"PLoS One"},{"key":"2025121223445558000_10.8.e033720.12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3109\/00365513.2014.930510","article-title":"Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial","volume":"74","author":"Bjerre","year":"2014","journal-title":"Scand J Clin Lab Invest"},{"key":"2025121223445558000_10.8.e033720.13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijcard.2015.01.020","article-title":"Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial","volume":"182","author":"Winkel","year":"2015","journal-title":"Int J Cardiol"},{"key":"2025121223445558000_10.8.e033720.14","doi-asserted-by":"publisher","DOI":"10.1159\/000324533"},{"key":"2025121223445558000_10.8.e033720.15","doi-asserted-by":"publisher","DOI":"10.1159\/000128994"},{"key":"2025121223445558000_10.8.e033720.16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.maturitas.2016.07.015","article-title":"Reference values for 34 frequently used laboratory tests in 80-year-old men and women","volume":"92","author":"Helmersson-Karlqvist","year":"2016","journal-title":"Maturitas"},{"key":"2025121223445558000_10.8.e033720.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114248"},{"key":"2025121223445558000_10.8.e033720.18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.archger.2016.03.015","article-title":"The association of serum cathepsin B concentration with age-related cardiovascular-renal subclinical state in a healthy Chinese population","volume":"65","author":"Wang","year":"2016","journal-title":"Arch Gerontol Geriatr"},{"key":"2025121223445558000_10.8.e033720.19","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.301704"},{"key":"2025121223445558000_10.8.e033720.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1246"},{"key":"2025121223445558000_10.8.e033720.21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013080860"},{"key":"2025121223445558000_10.8.e033720.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.01.009"},{"key":"2025121223445558000_10.8.e033720.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.09.011"},{"key":"2025121223445558000_10.8.e033720.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.12.032"},{"key":"2025121223445558000_10.8.e033720.25","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399958"},{"key":"2025121223445558000_10.8.e033720.26","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811401482"},{"key":"2025121223445558000_10.8.e033720.27","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/80.3.557"},{"key":"2025121223445558000_10.8.e033720.28","unstructured":"Allison PD . Survival analysis using SAS: a practical guide. 2nd edn. NC, USA: SAS institute Inc, 2010."},{"key":"2025121223445558000_10.8.e033720.29","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"2025121223445558000_10.8.e033720.30","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1802"},{"key":"2025121223445558000_10.8.e033720.31","doi-asserted-by":"publisher","DOI":"10.2307\/2290157"},{"key":"2025121223445558000_10.8.e033720.32","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamainternmed.2014.3773","article-title":"Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International observational clarify registry","volume":"174","author":"Steg","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2025121223445558000_10.8.e033720.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e356"},{"key":"2025121223445558000_10.8.e033720.34","article-title":"Influence of ejection fraction on outcomes and efficacy of sacubitril\/valsartan (lcz696) in heart failure with reduced ejection fraction","volume":"9","author":"Solomon","year":"2016","journal-title":"Circulation"},{"key":"2025121223445558000_10.8.e033720.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2844"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-033720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:45:05Z","timestamp":1765611905000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-033720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,20]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2019-033720"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-033720","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}